Trial Profile

Efficacy of apatinib (rivoceranib) combined with docetaxel in patients with EGFR-negative advanced non-small-cell lung cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
20 Jun 2018 New trial record
05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, recruitment is completed on Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com